D&D PharmaTech Co.
D&D Pharmatech Inc. engages in the research and development and manufacturing of pharmaceuticals in South Korea. It develops oral peptides, such as MET-002o, MET-224o, MET-097o, DD03, DD07, and DD14 programs for obesity indications in the development phase; injectable peptides, including DD01 for MASH indications; NLY12 and DD15 for obesity indications; and Pegsebrenatide (NLY01) for Parkinson's … Read more
D&D PharmaTech Co. (347850) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: -0.092x
Based on the latest financial reports, D&D PharmaTech Co. (347850) has a cash flow conversion efficiency ratio of -0.092x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-5.91 Billion) by net assets (₩63.92 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
D&D PharmaTech Co. - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how D&D PharmaTech Co.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
D&D PharmaTech Co. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of D&D PharmaTech Co. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Tatfook Tech
SHE:300134
|
-0.004x |
|
Postal Realty Trust Inc
NYSE:PSTL
|
0.031x |
|
Hanjin Kal
KO:18064K
|
0.007x |
|
MegaChips Corporation
F:MHC
|
0.045x |
|
Jiangsu Longda Superalloy Co. Ltd. A
SHG:688231
|
N/A |
|
Dogus Otomotiv Servis ve Ticaret AS
IS:DOAS
|
-0.041x |
|
Anhui Huilong Agricultural Means of Production Co Ltd
SHE:002556
|
0.153x |
|
Hyperion Metals Limited
PINK:TAOFF
|
0.000x |
Annual Cash Flow Conversion Efficiency for D&D PharmaTech Co. (2022–2024)
The table below shows the annual cash flow conversion efficiency of D&D PharmaTech Co. from 2022 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩70.11 Billion | ₩-21.80 Billion | -0.311x | -59.12% |
| 2023-12-31 | ₩46.65 Billion | ₩-9.12 Billion | -0.195x | +96.52% |
| 2022-12-31 | ₩9.44 Billion | ₩-53.08 Billion | -5.623x | -- |